A study of 12 million Facebook users suggests that using Facebook is associated with living longer - when it serves to maintain and enhance your real-world social ties.

Global interest in a Kiwi company's anti-aging drug is ramping up, with three major clinical trials now under way to test it against a range of ailments.

The powerful combination of two vitamins could be a hidden key to curing human diseases through regenerative medicine.

World-renowned Australian artist Stelarc -- perhaps best known for having an artificial ear construction inserted into his arm --

Nobel Prize winners say environmental groups, led by Greenpeace, have opposed biotechnological innovation in agriculture.

A review of the health technology and medical devices sectors shows the industry has the fastest growth in IT spending.

New Zealand-founded LanzaTech has been ranked thirteenth on CNBC's Disruptors list for 2016.

Kiwi biotech firm Ubiquitome is seeking clearance from the FDA to secure a Zika diagnostic test.

Orion Health, Waitemata DHB and University of Auckland are part of a $37 million healthcare research collaboration.

A San Francisco startup has developed a synthetic alternative to spider silk by engineering identical proteins.

Last Thursday we saw a tale of two biotech companies. If you need evidence investing in medical research stocks is a lottery, this is the story for you, writes Christopher Niesche.

A process that could turn harmful gases into useful products like car tyres shows why scientists need to keep challenging our understanding of what are the proteins vital to all life on Earth.

As a species we face a conundrum: we have become so good at survival that we face sustainability issues caused by our population and consumption, Eric Watson writes.

Nasdaq's biotech companies have returned 500 per cent gains to shareholders since 2011, versus 97 per cent for the Nasdaq's Internet stocks.

A new way of treating incurable illnesses such as cancer and Ebola could be possible after a scientific breakthrough that also sheds light on the origin of life.

It costs drugmakers US$2.56 billion to bring a new medicine to market - more than double the price of 11 years ago.

New Zealand-founded bio-fuels innovator LanzaTech has attracted US$60 million in its latest capital-raising round,

The lines of thousands of love poems and songs may have to be rewritten, according to Professor Alain Carpentier.

Computer giant's motto is 'Don't be evil', but some worry that tech purchase brings allure of defence contracts.

Auckland bio-fuels pioneer Lanzatech has been named the second "hottest" bio-technology company in the world and 4th hottest for bio-chemicals.

Human trials of a locally developed Parkinson's disease treatment have begun in New Zealand after the first round yielded promising results.

Mandatory emissions standards for new vehicles and an electrical "smart grid" are among a raft of ways New Zealand could tap into a global green economy.

Genome sequencing is “revolutionising” medicine, but could also impact on how society deals with criminals with a genetic predisposition towards violence.

Technology developed by New Zealand's LanzaTech will lie at the heart of a new Taiwanese joint venture.